Christopher Yea - 17 Nov 2025 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
CHIEF DEVELOPMENT OFFICER
Signature
/s/ Benjamin L. Palleiko, Attorney-in-Fact
Issuer symbol
KALV
Transactions as of
17 Nov 2025
Transactions value $
-$38,848
Form type
4
Filing time
19 Nov 2025, 16:11:54 UTC
Previous filing
26 Aug 2025
Next filing
21 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Yea Christopher CHIEF DEVELOPMENT OFFICER C/O KALVISTA PHARMACEUTICALS, INC, 200 CROSSING BOULEVARD, FRAMINGHAM /s/ Benjamin L. Palleiko, Attorney-in-Fact 19 Nov 2025 0001691102

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALV Common Stock Options Exercise +4.21K +3.18% 136K 17 Nov 2025 Direct F1
transaction KALV Common Stock Sale -$38.8K -2.68K -1.97% $14.48 134K 18 Nov 2025 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALV Restricted Stock Unit Options Exercise $0 -1.77K -33.33% $0.00 3.55K 17 Nov 2025 Common Stock 1.77K Direct F1, F4
transaction KALV Restricted Stock Unit Options Exercise $0 -2.43K -100% $0.00 0 17 Nov 2025 Common Stock 2.43K Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2 The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.16 to $14.4835 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date, subject to continued service through each vesting date.
F5 1/12th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date, subject to continued service through each vesting date.